Zhenghai Tang
Montreal, QC H2W1R7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Author Correction: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.
Journal: Nature
Published: March 14, 2026
Targeting phagocytosis checkpoints for cancer immunotherapy.
Journal: Nature reviews. Cancer
Published: October 23, 2025
Anticancer immune responses are hindered by cis interaction of inhibitory checkpoint SIRPα.
Journal: Science immunology
Published: October 10, 2025
Inhibitory immune checkpoints in cancer immunotherapy.
Journal: Science immunology
Published: September 26, 2025
CD2 and its ligands are involved in development and activation of MAIT cells.
Journal: The Journal of experimental medicine
Published: February 25, 2025
SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.
Journal: Nature
Published: November 20, 2024
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
Journal: Nature communications
Published: October 17, 2024
CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.
Journal: Nature immunology
Published: February 15, 2023
Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells.
Journal: Nature nanotechnology
Published: November 11, 2022
Cis interactions between CD2 and its ligands on T cells are required for T cell activation.
Journal: Science immunology
Published: August 05, 2022
Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 28, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026